Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience1 - Concepedia

Concepedia

Publication | Closed Access

Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience1

43

Citations

15

References

2003

Year

M M Aw, Rachel M. Taylor, Ajay Verma, Aileen Parke, A J Baker, Dino Hadzic, Paolo Muiesan, Mohamed Rela, Nigel Heaton, Giorgina Mieli‐Vergani,

Transplantation

Abstract

Five of seven pediatric liver transplant recipients with SRR experienced successful outcomes with basiliximab treatment without major side effects, indicating that it is a safe alternative to OKT3 and other antilymphocyte antibodies.

References

	Year	Citations

Page 1